The research training programme involves 12 Marie Curie Fellows working together with different methodologies and datasets gathered in different countries and from multiple perspectives. The programme will provide an insight into the mechanisms of action of GvL and GvHD in order to improve current therapies and develop and test novel ones via clinical trials and/or animal model experiments.
On-the-job training will be supplemented with structured workshops concerning HSCT research and network-wide training on project management skills, ethics, regulatory issues and cross-national research to exploit the expertise of each partner.
In order to promote and evidence the impact of this research and training programme, all researchers and partners will guarantee societal dissemination of the results to a wider national and international audience.
Each fellow will deliver a project which is defined and embedded within a work package structure
of the work programme and focused on one of the six research topics. Please see below for our
research topics and the associated fellow research projects.
Predicting GvHD and identification of novel biomarkers for GvHD.
Predicting GvHD by gene expression profiling and testing new targets
Assessment of Biomarkers
Monitoring GvHD and assessment of biomarkers for use post cellular therapy.
Monitoring biology of GvHD using biomarkers
Graft vs Leukemia (GvL)
GvL effects of NK cells against leukaemia cell lines.
Determining soluble serum markers and membrane bound NK-ligands for the prediction of antitumour immune GvL responses and GvHD
Adaptive repertoire profiling.
Use of an animal model for studying GvHD/GvL and cellular therapies
In vitro safety and efficacy assessment of novel therapeutics including antibodies, aptamers and cellular therapies by the use of a human in vitro skin explant model (Skimune™)
CMV infection post HSCT.
Development of genetically modified Tcells to target leukemic cells
MSC’s as therapy for GvHD and regenerative medicine.